中国医科大学学报
中國醫科大學學報
중국의과대학학보
JOURNAL OF CHINA MEDICAL UNIVERSITY
2015年
6期
528-532,537
,共6页
结直肠肿瘤%阿司匹林%预后%Meta分析
結直腸腫瘤%阿司匹林%預後%Meta分析
결직장종류%아사필림%예후%Meta분석
colorectal cancer%aspirin%prognosis%meta-analysis
目的:采用Meta分析探讨服用阿司匹林是否改善结直肠癌患者的预后。方法检索PubMed、EMBASE数据库中关于服用阿司匹林与结直肠癌预后关系的文献,提取整体生存以及肿瘤特异性生存的预后相关结果进行效应量的合并,对纳入的数据进行亚组分析、发表偏倚分析等。所有统计分析均采用Review Manager 5.2软件完成。结果共纳入13篇文献,共计结直肠癌患者43173例。Meta分析结果显示,服用阿司匹林的结直肠癌患者较未服用患者生存获益,并且在诊断后服用阿司匹林的结直肠癌患者整体生存和肿瘤特异性生存均较好,但是在诊断前服用阿司匹林的结直肠癌患者并没有显著的生存获益。结论诊断后服用阿司匹林可改善结直肠癌患者的预后生存。
目的:採用Meta分析探討服用阿司匹林是否改善結直腸癌患者的預後。方法檢索PubMed、EMBASE數據庫中關于服用阿司匹林與結直腸癌預後關繫的文獻,提取整體生存以及腫瘤特異性生存的預後相關結果進行效應量的閤併,對納入的數據進行亞組分析、髮錶偏倚分析等。所有統計分析均採用Review Manager 5.2軟件完成。結果共納入13篇文獻,共計結直腸癌患者43173例。Meta分析結果顯示,服用阿司匹林的結直腸癌患者較未服用患者生存穫益,併且在診斷後服用阿司匹林的結直腸癌患者整體生存和腫瘤特異性生存均較好,但是在診斷前服用阿司匹林的結直腸癌患者併沒有顯著的生存穫益。結論診斷後服用阿司匹林可改善結直腸癌患者的預後生存。
목적:채용Meta분석탐토복용아사필림시부개선결직장암환자적예후。방법검색PubMed、EMBASE수거고중관우복용아사필림여결직장암예후관계적문헌,제취정체생존이급종류특이성생존적예후상관결과진행효응량적합병,대납입적수거진행아조분석、발표편의분석등。소유통계분석균채용Review Manager 5.2연건완성。결과공납입13편문헌,공계결직장암환자43173례。Meta분석결과현시,복용아사필림적결직장암환자교미복용환자생존획익,병차재진단후복용아사필림적결직장암환자정체생존화종류특이성생존균교호,단시재진단전복용아사필림적결직장암환자병몰유현저적생존획익。결론진단후복용아사필림가개선결직장암환자적예후생존。
Objective To systematically assess the relationship between oral administration of aspirin and survival benefit for patients with colorec?tal cancer(CRC)by meta?analysis. Methods Relevant studies were identified through searching PubMed and EMBASE. Random?effects model was derived to composite the pooled hazard ratio for overall mortality and CRC?specific mortality. The subgroup analysis was conducted for included data,and the bias analysis was reported. Results Thirteen studies on aspirin therapy were finally included in this meta?analysis. The overall surviv?al benefit associated with oral administration of aspirin represented an HR of 0.83(95%CI:0.71?0.96). Oral administration of aspirin was also asso?ciated with CRC?specific survival(HR=0.77,95%CI:0.64?0.93). No evidence was observed of an association between prediagnostic aspirin use and CRC overall survival(HR=1.00,95%CI:0.85?1.18)or CRC?specific survival(HR=0.97,95%CI:0.83?1.13). Conclusion These findings provide further indication that post?diagnostic aspirin therapy can improve CRC prognosis.